Who is sponsoring NCT03138421?

NCT03138421 is sponsored by Abide Therapeutics.

What drugs are being tested in NCT03138421?

Interventions in NCT03138421: ABX-1431 HCl, Placebo.

What condition does NCT03138421 study?

NCT03138421 studies Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis.

Is NCT03138421 still recruiting?

NCT03138421 is currently completed. Last updated 25 January 2019.

Last reviewed 2019-01-25 · How we verify

NCT03138421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Central Pain Study for ABX-1431

Completed Phase 1 Last updated 25 January 2019

What this trial tests

Phase 1 trial testing ABX-1431 HCl in Neuromyelitis Optica Spectrum Disorder in 9 participants. Completed in 24 July 2018.

Timeline

1 August 2017

Primary endpoint
23 July 2018

24 July 2018

Quick facts

Lead sponsor	Abide Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	9
Start date	1 August 2017
Primary completion	23 July 2018
Estimated completion	24 July 2018
Sites	2 locations across United Kingdom

Drugs / interventions tested

ABX-1431 HCl
Placebo

Conditions studied

Neuromyelitis Optica Spectrum Disorder — all drugs for Neuromyelitis Optica Spectrum Disorder →
Transverse Myelitis — all drugs for Transverse Myelitis →
Multiple Sclerosis — all drugs for Multiple Sclerosis →
Longitudinally Extensive Transverse Myelitis — all drugs for Longitudinally Extensive Transverse Myelitis →

Sponsor

Abide Therapeutics — full company profile →

Who can join

18 and older, any sex, with Neuromyelitis Optica Spectrum Disorder or Transverse Myelitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy. During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain.
Tajti J, Szok D, Csáti A, Szabó Á, et al · · 2023 · cited 47× · PMID 36835524 · DOI 10.3390/ijms24044114
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ, Huestis MA, Amendolara B, Vandrey R, et al · · 2020 · cited 33× · PMID 33086126 · DOI 10.1016/j.pbb.2020.173059
Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders.
Jiang M, van der Stelt M. · · 2018 · cited 29× · PMID 30354159 · DOI 10.1021/acs.jmedchem.8b01405
Druggable Targets in Endocannabinoid Signaling.
Gregus AM, Buczynski MW. · · 2020 · cited 9× · PMID 32894511 · DOI 10.1007/978-3-030-50621-6_8
Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective.
Perin P, Mabou Tagne A, Enrico P, Marino F, et al · · 2020 · cited 8× · PMID 33329293 · DOI 10.3389/fneur.2020.505995

Verify or expand the search:

Other recruiting trials for Neuromyelitis Optica Spectrum Disorder

Currently open trials in the same condition.

NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
NCT05891379 — Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders · recruiting
NCT06180278 — Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) · Phase 4 · active not recruiting
NCT05966467 — Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies · recruiting

Other Abide Therapeutics trials

Trials by the same sponsor.

NCT03625453 — Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder · Phase 2 · completed
NCT03447756 — Titration Study of ABX-1431 · Phase 1 · completed
NCT03058562 — A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome · Phase 1 · completed
NCT02875678 — A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03138421 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abide Therapeutics
Last refreshed: 25 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03138421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing